Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA Back

HCV at CROI 2016       CROI: Summary from CROI 2016 for Hepatitis C Feedback from real-life: how is HCV therapy working outside of clinical trials? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (03/23/16)   HCV Treatment / Acute Treatment   CROI:Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens - (02/24/16)   CROI: Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (02/24/16)   CROI: Interactions Between ABT-493 plus ABT-530 combination and Rilpivirine or Raltegravir - (03/01/16)   CROI: TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r + Dasabuvir + RBV for HCV/HIV Co-Infection - (03/05/16)   CROI: Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (03/05/16)   CROI: Retreatment of HCV/HIV-Coinfected Patients Who Failed 12 Weeks of LDV/SOF - (03/05/16)   CROI: Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients with Acute HCV Infection - (03/01/16)   CROI: Lower Ribavirin Exposures in HIV+ Patients that Relapsed to Acute HCV Treatment: SWIFT-C - (03/24/16)   CROI: SOF/Rbv SWIFT-C Study Acute HCV Treatment: low RBV levels & relapse; Acute HCV - studies of 4, 6, 8 & 12 weeks - (03/23/16)   CROI: Ravidasvir/Sofosbuvir Yields Quick SVRs in Largest Genotype 4 Trial - (03/05/16)   APASL: Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies - (04/01/16)   APASL: Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study - (04/01/16)   APASL: High SVR Rates With ABT-493 + ABT-530 in Non-Cirrhotic Patients With HCV Genotypes 1, 2, 3 Infection - (02/22/16)   CROI: Real-life renal safety of "boosted TDF" in HIV/HCV-patients on SOF/LDV - (03/24/16)   CROI:Response to DAA-based regimens in HIV-HCV co-infected patients in real-life, France....patients with avg Fibroscan of 14.2 kPa / 67% of patients cirrhotic - (03/24/16)   HCV in Egypt   CROI: Hepatitis C in Egypt: A National Approach to Treatment, Manal El-Sayed MD - (03/24/16)   CROI: HCV in Egypt: History/Epidemiology, Care/Access/Treatment.... more than 90% Egyptian HCV is genotype 4 - (03/18/16)   Coffee   CROI: Protective Effect of Coffee Intake on Mortality of French HIV-HCVInfected Patients (ANRS CO13 HEPAVIH Cohort) - (03/01/16)   Sexual transmission MSM   CROI: "Chemsex" and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men...increased risk for HCV & STIs - (03/11/16)   CROI: Sexual Behaviour is Associated with Recently Acquired HCV in HIV/HCV Co-infected MSM - (03/11/16)   CROI: Prevalence & Factors of HCV Infection Among HIV-Negative & HIV-Positive MSM - (03/11/16)   CROI: Incidence of Hepatitis C Virus Infection in the HIV Outpatient Study (HOPS) Cohort: 2000-2013.... from 2011-2023 MSM HCV hazard ratio was 4.5 times greater vs IDUs (Table 2) - (03/11/16)   Guidelines Updates   NEW RECOMMENDATIONS IN THE UPDATED WHO: GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION - (03/07/16)   HCV Guidelines Updated Feb 24 2016 - (03/07/16)   Cascade of Care / Reinfection   CROI: Hepatitis C Screening and Linkage to Care [Cascade of Care] at a Comprehensive Health System (Detroit/Henry Ford health System)...78% not screened for HCV - (03/11/16)   CROI: HCV Treatment in Groups at Risk for Reinfection - talk at CROI by Oluwaseun Falade-Nwulia - (03/11/16)   CROI: Project INSPIRE: a Comprehensive Care Coordination Program for HCV-Infection Preliminary Year 1 Results - (03/07/16)   CROI: High HCV Cure Rates for Drug Users Treated with DAAs at an Urban Primary Care Clinic NYC- (03/05/16)   CROI: Primary Providers as Successful as Specialists in Treating HCV Infection - ASCEND Trial (02/24/16)   Risk for Progression   CROI: Residual risk of disease progression after hepatitis C cure in HIV-HCV co-infected patients - (03/11/16)   CROI: Liver Cancer in Patients Cured of HCV: Less Cirrhosis and Less Fat than Expected - (03/11/16)   CROI: Statin Dose and Type Tied to Lower Fibrosis Progression and Liver Cancer Incidence - (03/05/16)   CROI: Atorvastatin and Fluvastatin are Associated with Dose-Dependent Reductions in Cirrhosis and HCC Among Patients with HCV: Results from ERCHIVES - (03/01/16)   CROI: Poorly Controlled HIV Infection is a Risk Factor for Liver Fibrosis in the CNICS Cohort ...CD4 & Viral load predict progression to advanced fibrosis - (03/01/16)   HCV Drug Resistance   CROI: Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance - (03/11/16)   CROI: Resistance Associated Variants: Data From the NIAID SYNERGY Trial / Harvoni-Retreating Short Duration Therapy - (03/07/16)   CROI: CROI 2016 - Themed Discussion: Rants About HCV RAVS - (03/05/16)   CROI: HCV resistance to the daclatasvir/sofosbuvir combination across different HCV genotypes in the real life French Cohort - (03/24/16)